Mylan says GDUFA not discriminatory despite foreign inspection cost differential
This article was originally published in Scrip
Executive Summary
Mylan believes that any claims of bias against foreign manufacturers within the US FDA's proposed generic drug user fee plan are 'misplaced' and that the programme offers parity for all industry participants. The US firm, seen as a 'driving force’ behind the proposal, also sees the programme securing American competitiveness and jobs.